Transcriptional profiling of estrogen responses in ER-positive human breast cancer cell lines and model systems in vitro leads to changes in the transcription of large numbers of genes [8,9], but very little is known of these effects in vivo or how these effects vary between tumours and whether these molecular changes fully encompass the determinants of clinical response. The gene discussed is ESR1; the disease is neoplasm.